NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

NCT04615013 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Cervical Esophagus Adenocarcinoma
Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8
Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Gastroesophageal Junction Adenocarcinoma
Pathologic Stage II Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8
Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8
Thoracic Esophagus Adenocarcinoma

Interventions

DRUG: Capecitabine
DRUG: Carboplatin
DRUG: Docetaxel
DRUG: Fluorouracil
OTHER: Hafnium Oxide-containing Nanoparticles NBTXR3
RADIATION: Intensity-Modulated Radiation Therapy
DRUG: Leucovorin
DRUG: Oxaliplatin
DRUG: Paclitaxel

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]